Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
100%. Thanks for posting!
Hope our new IMPP shares (CISS) hold above $3 !!!
GLTA
SNGX sell off 6/20 must be MORE bad news
Go CALC!
Maybe I’ll get my $40 pre split back!
Riding MULN out to set new record.
$20k down to $200 soon to be $2…
Wow SNGX now .05 "pre-split"... Schaber trying to kill people or save lives???
Nice work
To think SNGX over $4 few days ago…
GLTA
I only need SNGX 12s !
GLTA
17 shares traded today !
Go calc !
SNGX from other board: "BARDA Contract Award"
"BARDA was expected (I thought) to release news on the contract proposals for Sudan-Ebolavirus and Marburg Virus very soon, if not already. Although monovalent vaccines are of primary focus per BARDA, Soligenix's bivalent SuVax and MarVax vaccine have proven to give 100% protection, and relatively quickly, which is ultimately what BARDA claims they're after.
Does anyone have any insight into this decision and if/when contract awards will be announced?"
Any others seen / heard of this potential upcoming news ?
GLTA
WTH today SNGX ???!!!
Bear-Trap???!!!. Current $2.10 with $2.31 Bid, and $7.10 ASK !
WTf
Crazy GRAY now merged to be CALC so low & projected pps $14??
Great deal or failure ?
GLTA
That would be appropriate & great, but I've never seen a forward split to counter reverse done..
GLTA
I don't think date for that meeting was yet confirmed?
SNGX 4/05/2023 receives approval for HyBryte...
- "Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302. 7:30 am ET April 5, 2023 (PR Newswire).
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Adopted Names (USAN) Council has approved the use of the nonproprietary name of "hypericin sodium" for the novel active ingredient in both HyBryte™ (research name SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL)and SGX302 for the treatment of mild-to-moderate psoriasis.
- "We are pleased that USAN has approved the proposed name," statedChristopher J. Schaber, PhD, President and Chief Executive Officer ofSoligenix. "We look forward to continuing to work with the World Health Organization (WHO) to advance the International Nonproprietary Name (INN) hypericin from a proposed INN to a recommended INN, which is expected to occur later this year."
- Information on hypericin sodium will be posted on the USAN website (www.ama-assn.org/go/usan) before the end of 2023 and will be submitted to the U.S. Pharmacopeial Convention for publication in the U.S. Pharmacopeia Dictionary of USAN and International Drug Names.
About USAN
The USAN Council serves health professionals in the U.S. by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships to ensure that drug information is communicated accurately and unambiguously. The USAN Council aims for global standardization and unification of drug nomenclature by working closely with the International Nonproprietary Name Program of WHO and various national nomenclature groups.
About Synthetic Hypericin Sodium
Visible light-activated synthetic hypericin sodium is a novel, first-in-class, photodynamic therapy (PDT) that is expected to avoid much of the long-term risks associated with other PDT treatments. Synthetic hypericin sodium is a potent photosensitizer that is topically applied to skin lesions and taken up by cutaneous T-cells. With subsequent activation by safe, visible light, T-cell apoptosis is induced, addressing the root cause of both CTCL and psoriasis lesions. Other PDTs have shown efficacy in psoriasis with a similar apoptotic mechanism, albeit using ultraviolet (UV) light associated with more severe potential long-term safety concerns. The use of visible light in the red-yellow spectrum has the advantage of deeper penetration into the skin (much more than UV light) potentially treating deeper skin disease and thicker plaques and lesions, similar to what was observed in previous clinical trials.
- This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with both the frequently used DNA-damaging drugs and other phototherapies that are dependent on UV A or B exposure. The use of synthetic hypericin sodium coupled with safe, visible light also avoids the risk of serious infections and cancer associated with the systemic immunosuppressive treatments used in CTCL and psoriasis.
- In a published Phase 1/2 proof of concept clinical study using synthetic hypericin sodium, efficacy was demonstrated in patients with CTCL (58.3% response, p=0.04) as well as psoriasis (80% response, p<0.02).
- The recently published Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin)studyenrolled a total of 169 patients (166 evaluable) with Stage IA, IB or IIA CTCL. The trial consisted of three treatment cycles. Treatments were administered twice weekly in 6-week cycles. In the first double-blind treatment cycle, 116 patients received HyBryte™ (the tradename used in CTCL) treatment and 50 received placebo treatment of their index lesions. A total of 16% of the patients receiving HyBryte™ achieved at least a 50% reduction in their lesions (using the standard Composite Assessment of Index Lesions Severity [CAILS] score) compared to only 4% of patients in the placebo group after just 6 weeks of treatment (p=0.04). Further treatment with HyBryte™ increased the number of treatment successes to 40% and 49% after 12 and 18 weeks, respectively (p<0.0001 for both). Additional analyses also indicated that HyBryte™ is equally effective in treating both plaque (42% treatment response rate after 12 weeks treatment, p<0.0001 relative to placebo treatment in Cycle 1) and patch (37%, p=0.0009) lesions of CTCL, a particularly relevant finding given the historical difficulty in treating plaque lesions. This is also relevant to psoriasis where the lesions can be thicker than the patches observed in CTCL.
In a subset of patients evaluated during their third treatment cycle, it was demonstrated that HyBryte™ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3, HyBryte™ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.
- A HyBryte™ new drug application (NDA) has been submitted for the treatment of CTCL with the U.S. Food and Drug Administration (FDA). It is currently the subject of an FDA Refusal to File(RTF) letter, as upon preliminary assessment, the FDA determined that it was not sufficiently complete to permit substantive review. A Type A meeting with the FDA has been scheduled to gain further clarity and to respond to the issues identified in the RTF letter, as well as to seek additional guidance concerning information that the agency would require for a resubmitted NDA to be deemed acceptable.
- SGX302 (synthetic hypericin sodium) is currently being evaluated in a Phase 2a clinical trial targeting enrollment of up to 42 patients ages 18 years or older with mild to moderate, stable psoriasis covering 2 to 30% of their body. Patients will undergo treatments for a total of 18 weeks and, on completion, will be followed for a 4-week follow-up period in which patients will not receive other psoriasis treatments. The study is divided into two parts. In Part A, 5-10 patients will be assigned open-label SGX302 (0.25% hypericin) at the time of enrollment. Once the tolerability and response to SGX302 has been established, Part B of the protocol will commence. In Part B, patients will be randomized to double-blind treatment groups at a ratio 1:1 of active drug to placebo ointment."
GLTA
GDXU Forward split 2:1 or 4:1 ???!!!
"Bank of Montreal (Quebec) stock split history picture
Bank of Montreal (Quebec) (GDXU) has 1 split in our Bank of Montreal (Quebec) stock split history database. The split for GDXU took place on October 31, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of GDXU owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split."
GLTA
Gold up nice 4/4 so JNUG on our way...
GLTA
Gold up nice 4/4 so GDXU on our way...
GLTA
MULN buyback for all the F'n DILUTION !!!
GLAT
What in the bloody heck MULN???
It doesn't seem good judgement to close out at a 90% loss, but I guess better than a 99% loss?
MULN Flood Gates wide OPEN ???!!!
Weeks now???
So JNUG went up $10 or 30% when gold moved up $50.
Will we see JNUG $200 when gold is $2400 in next 3-4 Months?!
GLTA
So GDXU went up $10 or 25% when gold moved up $50.
Will we see GDXU $200 when gold is $2400 in next 3-4 Months?!
GLTA
DWAC on the up & UP !
GLTA
So much for the supposed BS "vote". GRAY did whatever they wanted...
"Graybug Announces Name and Trading Symbol Change. GlobeNewswireMarch 20, 2023
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its trading symbol to "CALC." The Company's common stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol "CALC." The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica, Inc. (CalciMedica).
About Graybug:
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. Founded in 2011 based on technology licensed from the Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, CA, and Baltimore, MD. For more information, please visit www.graybug.vision.
About CalciMedica:
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica's proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com."
GRAY reverse split 1:14 on 3/20/2023...
$5.50 pre-market means .39 pre split.
Rot in hell GRAY execs....
Did GRAY r/s ???
Strange Bid/Ask???
GLTA
I'd appreciate just $1 of my $2 avg back on MULN !
NEVER gonna happen...
GLTA
About time IMPP !
Someone willing to sell a FEW every day…
SNGX likely trade under 20k shares again today
SNGX not many sells but $3.06 on bid says they’ll pull it lower still….
GLTA
Ha YES !
IMPP huge buying opportunity with today's low???
C'mon... What am I missing?
" - Revenues of $37.9 million in Q4 22' - up $33.9 million or 847.5% from Q4 21'.
- Net income of $13.8 million in Q4 22' compared to a $1.5 million loss in Q4 21'.
- EBITDA1 of $17.8 million in Q4 22' up $17.0 million or 2,125% from Q4 21'.
- Cash and time deposits of $118.9 million as of December 31, 2022 - 1.7 times higher than our current market cap.
- For 12M 22' we generated a Net Income of $29.5 million which is equivalent to 43% of our current market cap."
Wow !
GLTA
And now refused so SNGX at .20 pre split
SNGX +30% after hours…
What’s UP
GLTA
SNGX nice new OS less than 3,000,000 !
“The reverse stock split will reduce the number of shares of Soligenix’s common stock outstanding from 43,335,174 shares to approximately 2,889,012”
GLTA
Dang that may be same for me….
SNGX confirmed 1:15 gonna open tomorrw $6, and likely be back sub $2s within 2 weeks...
*Without confirmed positive movement in their pipeline*...
Skanks...
GLTA
TLSS looking UP since start of year...
Lets keep it UP TLSS !